世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の帯状疱疹治療市場 2019-2023年

Global Herpes Zoster Treatment Market 2019-2023

IRTNTR30133

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年11月US$2,500
シングルユーザライセンス
102

サマリー

この調査レポートは世界の帯状疱疹治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

101 pages, November 2018

About this market


With the emerging innovative vaccines for disease management, there is a growing demand for herpes zoster treatment drugs. Until the development of vaccines, the treatment for herpes zoster was dependent completely on drug therapies. However, vendors have been focusing on developing several new therapies for the treatment and prevention of shingles. For instance, in October 2017, Shingrix was launched by GlaxoSmithKline for the treatment of shingles. The vaccine is much more effective than ZOSTAVAX, which was the only approved vaccine for shingles in older adults. Technavio’s analysts have predicted that the herpes zoster treatment market will register a CAGR of almost 14% by 2023.

Market Overview


Rising incidence of herpes zoster
Factors such as exposure to ultraviolet radiation may suppress the cell-mediated immunity, which can be a major factor responsible for the growing incidence of herpes zoster. Patients being treated for cancer and affected with advanced HIV infection are at a greater risk of developing shingles, which is expected to boost the growth of the global herpes zoster treatment market.
Weak pipeline for herpes zoster
The number of herpes zoster pipeline agents are very limited despite the growing incidence of the infection worldwide, which is likely to hamper the growth of the global herpes zoster treatment market.
For the detailed list of factors that will drive and challenge the growth of the herpes zoster treatment market during the 2019-2023 period, view our report.

Competitive Landscape


The market appears to be fragmented and with the presence of several companies including Abbott and GlaxoSmithKline, the competitive environment is quite intense. Factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster, will provide considerable growth opportunities to herpes zoster treatment companies. Abbott, GlaxoSmithKline, Merck, and Novartis are some of the major companies covered in this report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Vaccination - Market size and forecast 2018-2023
- Drug therapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Abbott
- GlaxoSmithKline
- Merck
- Novartis
PART 15: APPENDIX
- Research methodology
- List of abbreviations
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for the treatment of herpes zoster
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Vaccination - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Vaccination - Year-over-year growth 2019-2023 (%)
Exhibit 22: Drug therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Drug therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Abbott - Vendor overview
Exhibit 43: Abbott - Business segments
Exhibit 44: Abbott - Organizational developments
Exhibit 45: Abbott - Geographic focus
Exhibit 46: Abbott - Segment focus
Exhibit 47: Abbott - Key offerings
Exhibit 48: GlaxoSmithKline - Vendor overview
Exhibit 49: GlaxoSmithKline - Business segments
Exhibit 50: GlaxoSmithKline - Organizational developments
Exhibit 51: GlaxoSmithKline - Geographic focus
Exhibit 52: GlaxoSmithKline - Segment focus
Exhibit 53: GlaxoSmithKline - Key offerings
Exhibit 54: Merck - Vendor overview
Exhibit 55: Merck - Business segments
Exhibit 56: Merck - Organizational developments
Exhibit 57: Merck - Geographic focus
Exhibit 58: Merck - Key offerings
Exhibit 59: Novartis - Vendor overview
Exhibit 60: Novartis - Business segments
Exhibit 61: Novartis - Organizational developments
Exhibit 62: Novartis - Geographic focus
Exhibit 63: Novartis - Segment focus
Exhibit 64: Novartis - Key offerings


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る